| Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|
Revenues | ||||||||
393,941 | 366,378 | 336,123 | 301,501 | 263,429 | 242,132 | 217,256 | 179,218 | 148,676 |
Cost of revenues | ||||||||
225,653 | 214,393 | 204,652 | 185,598 | 160,926 | 149,324 | 139,648 | 121,091 | 111,812 |
Gross profit | ||||||||
168,288 | 151,985 | 131,471 | 115,903 | 102,503 | 92,808 | 77,608 | 58,127 | 36,864 |
Operating expenses: | ||||||||
Selling and marketing | ||||||||
68,234 | 63,878 | 58,528 | 55,385 | 47,842 | 40,485 | 37,550 | 34,166 | 30,047 |
Research and development | ||||||||
39,608 | 31,032 | 26,237 | 22,635 | 18,887 | 17,111 | 14,437 | 12,900 | 9,814 |
Distribution | ||||||||
32,484 | 28,579 | 26,211 | 26,001 | 21,246 | 18,888 | 17,916 | 14,751 | 13,918 |
General and administrative | ||||||||
41,813 | 32,781 | 35,124 | 34,069 | 32,326 | 27,530 | 23,206 | 22,774 | 19,532 |
Total operating expenses | ||||||||
182,139 | 156,270 | 146,100 | 138,090 | 120,301 | 104,014 | 93,109 | 84,591 | 73,311 |
Income (loss) from operations | ||||||||
-13,851 | -4,285 | -14,629 | -22,187 | -17,798 | -11,206 | -15,501 | -26,464 | -36,447 |
Other income (expense): | ||||||||
Interest expense, net | ||||||||
-756 | -1,000 | -1,115 | -863 | -611 | -2,766 | 4,714 | 4,597 | 6,522 |
Interest income | ||||||||
- | - | - | - | - | - | - | - | 35 |
Other income (expense), net | ||||||||
-863 | -930 | 561 | -10 | -397 | -148 | -288 | 117 | -268 |
Total other expense | ||||||||
-1,619 | -1,930 | -554 | -873 | -1,008 | -2,914 | -5,002 | -4,480 | -6,755 |
Net income (loss) before income taxes | ||||||||
-15,470 | -6,215 | -15,183 | -23,060 | -18,806 | -14,120 | -20,503 | -30,944 | -43,202 |
Provision for (benefit from) income taxes | ||||||||
-145 | 1,102 | 1,077 | 1,253 | -245 | 1,033 | 899 | 768 | 265 |
Net income (loss) | ||||||||
-15,325 | -7,317 | -16,260 | -24,313 | -18,561 | -15,153 | - | - | - |
Less: Net loss attributable to noncontrolling interests | ||||||||
-1,333 | -2,546 | -918 | -367 | 0 | - | - | - | - |
Net income (loss) attributable to NxStage Medical, Inc. | ||||||||
-13,992 | -4,771 | -15,342 | -23,946 | -18,561 | -15,153 | -21,402 | -31,712 | -43,467 |
Add: Accretion to redemption value of noncontrolling interests | ||||||||
481 | 0 | 0 | - | - | - | - | - | - |
Net income (loss) attributable to common stockholders | ||||||||
-14,473 | -4,771 | -15,342 | - | - | - | - | - | - |
Weighted-average shares outstanding: | ||||||||
Net loss per share, basic and diluted (in dollars per share) | ||||||||
-0.22 | -0.07 | -0.24 | -0.39 | -0.31 | -0.26 | -0.39 | -0.66 | -0.93 |
Weighted-average shares outstanding, basic and diluted (in shares) | ||||||||
65,856 | 64,520 | 63,384 | 61,700 | 60,261 | 57,890 | - | - | - |
Other comprehensive income (loss): | ||||||||
Unrealized income (loss) on derivative instruments, net of income taxes | ||||||||
1,001 | -802 | -395 | - | - | - | - | - | - |
Other income (loss) | ||||||||
-1,427 | 1,268 | 1,444 | - | - | - | - | - | - |
Weighted-average shares outstanding, basic and diluted | ||||||||
- | - | - | - | - | - | 54,217 | 48,188 | 46,627 |
Total other comprehensive income (loss) | ||||||||
2,428 | -2,070 | -1,839 | -2,404 | -258 | 538 | -153 | - | - |
Total comprehensive income (loss) | ||||||||
-12,897 | -9,387 | -18,099 | -26,717 | -18,819 | -14,615 | - | - | - |
Less: Comprehensive loss attributable to noncontrolling interests | ||||||||
-1,333 | -2,546 | -918 | -367 | 0 | - | - | - | - |
Foreign currency gain (loss) | ||||||||
- | - | - | - | - | - | - | -486 | - |
Other gain (loss) | ||||||||
- | - | - | - | - | - | - | 6 | - |
Total comprehensive income (loss) attributable to NxStage Medical, Inc. | ||||||||
-11,564 | -6,841 | -17,181 | -26,350 | -18,819 | -14,615 | -21,555 | -32,192 | - |